Inspira Technologies (IINNW) wins U.S. patent for ART500 tech device

Rhea-AI Filing Summary

Inspira Technologies Oxy B.H.N. Ltd. reports that it has received U.S. patent approval for its ART500 core technology. The company describes this patent in its press release title as a key asset that could position it to address an estimated $20 billion market, underscoring management’s view of the technology’s commercial potential.

The filing also notes that the first, second, and fourth paragraphs of the press release and its “Forward-Looking Statements” section are incorporated by reference into Inspira’s existing shelf and equity compensation registration statements on Forms F-3 and S-8. This means the patent-related disclosure and related forward-looking commentary are now formally part of those registration documents.

Insights

Healthcare technology & IP analyst

U.S. patent on ART500 strengthens Inspira’s intellectual property position.

The company discloses that it has received U.S. patent approval for its ART500 core technology and highlights this in a dedicated press release. Securing a patent on what it calls core technology can help protect its product concept and may support future commercialization or partnership discussions, especially in markets where intellectual property is a key competitive factor.

The press release title references an estimated $20 billion market, signaling management’s view of a large addressable opportunity tied to ART500. The filing also incorporates specific paragraphs of the press release and the forward-looking statements section into existing Form F-3 and Form S-8 registration statements, ensuring that this patent and related expectations are reflected in Inspira’s broader disclosure framework. Actual financial impact will depend on how the ART500 technology is developed and adopted over time.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2025 (Report No. 2)

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F        ☐ Form 40-F

CONTENTS

On August 22, 2025, Inspira Technologies Oxy B.H.N. Ltd., or the Registrant, issued a press release titled “Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first, second, and fourth paragraphs and the section titled “Forward-Looking Statements” in the press release are incorporated by reference into the Registrant’s Registration Statements on Form F-3 (Registration Nos. 333-266748, 333-284308, and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980 and 333-285565), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on August 22, 2025, titled “Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.
Date: August 22, 2025	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

2

FAQ

What key update does Inspira Technologies (IINNW) report in this Form 6-K?

Inspira Technologies Oxy B.H.N. Ltd. reports that it has received U.S. patent approval for its ART500 core technology, as described in an accompanying press release.

How large is the market Inspira targets with the ART500 technology?

In the press release title referenced in the filing, the company describes the ART500 core technology as positioning it to address an estimated $20 billion market.

Which Inspira registration statements incorporate this ART500 patent disclosure?

The filing incorporates parts of the press release into Inspira’s Registration Statements on Form F-3 (Nos. 333-266748, 333-284308, 333-289324) and Form S-8 (Nos. 333-259057, 333-277980, 333-285565).

Which sections of the ART500 press release are incorporated by reference?

The first, second, and fourth paragraphs of the press release, along with the section titled “Forward-Looking Statements,” are incorporated by reference into the company’s registration statements.

Does this Form 6-K include the full ART500 patent press release text?

The Form 6-K states that the press release is furnished as Exhibit 99.1, titled “Inspira Receives U.S. Patent Approval for the ART500 Core Technology, Key Patent Positions the Company to Dominate $20 Billion Estimated Market.”

Who signed the Form 6-K for Inspira Technologies (IINNW)?

The report was signed on behalf of Inspira Technologies Oxy B.H.N. Ltd. by Dagi Ben-Noon, the company’s Chief Executive Officer.